These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25101565)

  • 21. Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.
    Levard A; Derbel O; Méeus P; Ranchère D; Ray-Coquard I; Blay JY; Cassier PA
    BMC Cancer; 2013 Mar; 13():109. PubMed ID: 23496996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
    Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
    Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
    Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
    Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.
    Siraj MA; Pichon C; Radu A; Ghinea N
    J Cell Mol Med; 2012 Sep; 16(9):2010-6. PubMed ID: 22129368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
    Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
    Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study.
    Stacchiotti S; Baldi GG; Frezza AM; Morosi C; Greco FG; Collini P; Barisella M; Dagrada GP; Zaffaroni N; Pasquali S; Gronchi A; Huang P; Ingrosso M; Tinè G; Miceli R; Casali PG
    Eur J Cancer; 2023 Dec; 195():113391. PubMed ID: 37918286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
    Zhao Q; Guo J; Wang G; Chu Y; Hu X
    Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
    van Cruijsen H; van der Veldt AA; Vroling L; Oosterhoff D; Broxterman HJ; Scheper RJ; Giaccone G; Haanen JB; van den Eertwegh AJ; Boven E; Hoekman K; de Gruijl TD
    Clin Cancer Res; 2008 Sep; 14(18):5884-92. PubMed ID: 18794101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization.
    Matsumoto S; Saito K; Takakusagi Y; Matsuo M; Munasinghe JP; Morris HD; Lizak MJ; Merkle H; Yasukawa K; Devasahayam N; Suburamanian S; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2014 Sep; 21(8):1145-55. PubMed ID: 24597714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
    Stacchiotti S; Tortoreto M; Bozzi F; Tamborini E; Morosi C; Messina A; Libertini M; Palassini E; Cominetti D; Negri T; Gronchi A; Pilotti S; Zaffaroni N; Casali PG
    Clin Cancer Res; 2013 Sep; 19(18):5192-201. PubMed ID: 23888069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
    Stacchiotti S; Saponara M; Frapolli R; Tortoreto M; Cominetti D; Provenzano S; Negri T; Dagrada GP; Gronchi A; Colombo C; Vincenzi B; Badalamenti G; Zuco V; Renne SL; Collini P; Morosi C; Dei Tos AP; Bello E; Pilotti S; Casali PG; D'Incalci M; Zaffaroni N
    Eur J Cancer; 2017 May; 76():84-92. PubMed ID: 28284173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.
    Torok S; Vegvari A; Rezeli M; Fehniger TE; Tovari J; Paku S; Laszlo V; Hegedus B; Rozsas A; Dome B; Marko-Varga G
    Br J Pharmacol; 2015 Feb; 172(4):1148-63. PubMed ID: 25363319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
    del Puerto-Nevado L; Rojo F; Zazo S; Caramés C; Rubio G; Vega R; Chamizo C; Casado V; Martínez-Useros J; Rincón R; Rodríguez-Remírez M; Borrero-Palacios A; Cristóbal I; Madoz-Gúrpide J; Aguilera O; García-Foncillas J
    Br J Cancer; 2014 May; 110(11):2700-7. PubMed ID: 24786599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
    Bruno A; Mortara L; Baci D; Noonan DM; Albini A
    Front Immunol; 2019; 10():771. PubMed ID: 31057536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Monocytic Myeloid-Derived Suppressor Cells in Whole Blood Predict Poor Prognosis in Patients with Plasma Cell Myeloma.
    Bae MH; Park CJ; Suh C
    J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.
    Bose A; Taylor JL; Alber S; Watkins SC; Garcia JA; Rini BI; Ko JS; Cohen PA; Finke JH; Storkus WJ
    Int J Cancer; 2011 Nov; 129(9):2158-70. PubMed ID: 21170961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
    Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
    Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
    Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.